Intelligence Platform

Patents

Browse 1,015 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed

patent

US 10435473

Stabilized formulations containing anti-interleukin-4 receptor (IL-4R) antibodies

REGENERON PHARMACEUTICALS, INC. · Granted Tue Oct 08 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 03 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10428008

Nitroalkene non steroidal anti-inflammatory drugs (NA-NSAIDs) and methods of treating infl

INSTITUT PASTEUR DE MONTEVIDEO · Granted Tue Oct 01 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 26 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10426797

Compositions and methods for treating cancer with anti-CD33 immunotherapy

United State of America, As Represented by the Secretary, Dept. of Health and Human Services · Granted Tue Oct 01 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 26 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10421945

Agents and methods to elicit anti-tumor immune response

The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Sep 24 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 19 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10421805

Anti-hepatitis C antibodies and antigen binding fragments thereof

United Kingdom Research and Innovation · Granted Tue Sep 24 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 19 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10421804

Anti-Zika virus antibodies and methods of use

REGENERON PHARMACEUTICALS, INC. · Granted Tue Sep 24 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 19 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10420851

Stabilized radiolabeled anti-CD45 immunoglobulin compositions

Actinium Phamaceuticals, Inc. · Granted Tue Sep 24 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 19 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10407485

Murine anti-NY-ESO-1 T cell receptors

The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Sep 10 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 05 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10406225

Anti-EphA2 antibodies and methods of use thereof

The Regents of the University of California · Granted Tue Sep 10 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 05 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10391170

Stable anti-OSMR antibody formulation

Kiniksa Pharmaceuticals, GmbH · Granted Tue Aug 27 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 22 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10363292

Vaccination with anti-tick antigens to control multiple tick species and disease transmiss

The United States of America, as represented by the Secretary of Agriculture · Granted Tue Jul 30 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 25 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10358495

Anti-LAG3 antibodies and uses thereof

REGENERON PHARMACEUTICALS, INC. · Granted Tue Jul 23 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 18 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10358487

Anti-ANGPTL3 antibodies and uses thereof

REGENERON PHARMACEUTICALS, INC. · Granted Tue Jul 23 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 18 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10351598

Peptide with anti-obesity and anti-diabetic efficacy and use thereof

CAREGEN CO., LTD. · Granted Tue Jul 16 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 11 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10351597

Peptide with anti-obesity and anti-diabetes activity and use thereof

CAREGEN CO., LTD. · Granted Tue Jul 16 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 11 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10342869

Compositions comprising anti-CD38 antibodies and lenalidomide

The Regents of the University of California · Granted Tue Jul 09 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 04 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10336833

Conjugated anti-CD38 antibodies

Takeda Pharmaceutical Company Limited · Granted Tue Jul 02 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 27 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10336824

Anti-PDL1 antibodies, activatable anti-PDL1 antibodies, and methods of thereof

CytomX Therapeutics, Inc. · Granted Tue Jul 02 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 27 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10329339

Anti-human papillomavirus 16 E6 T cell receptors

The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Jun 25 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 20 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10329338

Nucleic acid construct encoding an agonistic anti-CD40 antibody and a type I interferon

The Regents of the University of Colorado · Granted Tue Jun 25 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 20 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10316105

Anti-TIE2 antibodies and uses thereof

REGENERON PHARMACEUTICALS, INC. · Granted Tue Jun 11 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 06 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10314950

Anti-adhesive barrier membrane using alginate and hyaluronic acid for biomedical applicati

The Board of Regents of the University of Texas System · Granted Tue Jun 11 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 06 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10301393

Methods of treating multiple sclerosis using anti-CD20 antibodies

VACCINEX, INC. · Granted Tue May 28 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 23 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10301380

Anti-jagged 1/jagged 2 cross-reactive antibodies, activatable anti-jagged antibodies and m

CytomX Therapeutics, Inc. · Granted Tue May 28 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 23 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted